Ulkuskrankheit: Klinische Bewertung 2006

[1]  J. Labenz,et al.  Ulcusheilung durch Helicobacter-pylori-Eradikation: Genügt eine Woche Therapie? , 2008 .

[2]  F. Chan,et al.  Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors , 2006, The American Journal of Gastroenterology.

[3]  D. Praticò,et al.  Coxibs and cardiovascular side-effects: from light to shadow. , 2006, Current pharmaceutical design.

[4]  P. Malfertheiner,et al.  The effect of single‐dose naproxen on eicosanoid formation in human gastroduodenal mucosa , 2006, Alimentary pharmacology & therapeutics.

[5]  J. Johanson,et al.  Healing of Gastric Ulcers with Esomeprazole Versus Ranitidine in Patients Who Continued to Receive NSAID Therapy: A Randomized Trial , 2005, The American Journal of Gastroenterology.

[6]  D. Graham,et al.  Helicobacter pylori virulence factors: facts and fantasies , 2005, Current opinion in gastroenterology.

[7]  K. Chu,et al.  Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. , 2005, The American journal of medicine.

[8]  P. Moayyedi,et al.  Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. , 2005, Gastroenterology.

[9]  C. Hawkey,et al.  Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors , 2005, The American Journal of Gastroenterology.

[10]  G. I. Leontiadis,et al.  Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding , 2005, BMJ : British Medical Journal.

[11]  V. Wong,et al.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. , 2005, The New England journal of medicine.

[12]  N. Vakil,et al.  Seven‐day therapy for Helicobacter pylori in the United States , 2004, Alimentary pharmacology & therapeutics.

[13]  A. Straszak,et al.  Efficacy and Tolerability of Pantoprazole Compared with Misoprostol for the Prevention of NSAID-Related Gastrointestinal Lesions and Symptoms in Rheumatic Patients , 2004, Digestion.

[14]  M. D’Elios,et al.  Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. , 2003, Microbes and infection.

[15]  J. Pelletier,et al.  Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs , 2003, Annals of the rheumatic diseases.

[16]  B. Whittle.  Gastrointestinal effects of nonsteroidal anti‐inflammatory drugs , 2003, Fundamental & clinical pharmacology.

[17]  P. Malfertheiner,et al.  Helicobacter pylori eradication and gastric ulcer healing — comparison of three pantoprazole‐based triple therapies , 2003, Alimentary pharmacology & therapeutics.

[18]  R. Flower.  The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.

[19]  P. Malfertheiner,et al.  High rate of post‐therapeutic resistance after failure of macrolide–nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second‐line therapies in a randomized study , 2002, Alimentary pharmacology & therapeutics.

[20]  D. Graham,et al.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. , 2002, Archives of internal medicine.

[21]  Justin C.Y. Wu,et al.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial , 2002, The Lancet.

[22]  R. Hunt,et al.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis , 2002, The Lancet.

[23]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[24]  E. El-Omar,et al.  Alterations in gastric physiology in Helicobacter pylori infection: causes of different diseases or all epiphenomena? , 1997, Italian journal of gastroenterology and hepatology.

[25]  R. Spiller,et al.  Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. , 1996, Gastroenterology.

[26]  J. Mayet,et al.  An oesophageal reflux patient support group. The first two years experience: demand, organization and benefits , 1993 .

[27]  F. Chan.  NSAID-Induced Peptic Ulcers and Helicobacter pylori Infection , 2005, Drug safety.

[28]  E. El-Omar,et al.  Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. , 1996, Scandinavian journal of gastroenterology. Supplement.

[29]  P. Malfertheiner,et al.  Helicobacter pylori and the pathogenesis of duodenal ulser disease , 1993 .

[30]  P. Sipponen.  Natural history of gastritis and its relationship to peptic ulcer disease. , 1992, Digestion.